natgillin/translations-raw huggingface dataset:
Der skal klargøres 2 infusionsposer til infusionen 1. dag og 2. dag (100 mg til 1. dag og 900 mg til 2. dag). 
Two infusion bags should be prepared for the infusion on Days 1 and 2 (100 mg for Day 1 and 900 mg for Day 2).
Kaplan-Meier-kurver for progressionsfri overlevelse er vist i figur 5. 
Kaplan-Meier curves for progression-free survival (PFS) are shown in Figure 5.
Follikulær versus non-follikulær var også en stratificeringsfaktor for studiet men er ikke en stratificeringsfaktor i subgruppe-analysen af patienter med follikulært lymfom. 
Follicular versus non-follicular was also a stratification factor for the study but is not applicable in the subgroup analysis of patients with FL. § Best response within 12 months of start of treatment
Resultaterne for progressionsfri overlevelse i post-hoc analysen er i overensstemmelse med den primære analyse, og signifikansen er uændret. 
The PFS results in the post hoc analysis are consistent with the primary analysis and its significance is unchanged and the safety profile is consistent with the primary analysis.
Tabel 3 Follikulært lymfom: Gazyvaro-dosis, der skal administreres under induktionsbehandling efterfulgt af vedligeholdelsesbehandling 
Table 3 Follicular lymphoma: Dose of Gazyvaro to be administered during induction treatment, followed by maintenance treatment
Biotransformation Obinutuzumabs metabolisme er ikke direkte undersøgt. 
The metabolism of obinutuzumab has not been directly studied.
Obinutuzumab er et rekombinant monoklonalt, humaniseret og glycoengineered Type II anti-CD20antistof af IgG1-isotypen. 
Obinutuzumab is a recombinant monoclonal humanised and glycoengineered Type II anti-CD20 antibody of the IgG1 isotype.
Det gives over flere timer i et drop (infusion i en vene). 
It is given into a vein as a drip (intravenous infusion) over several hours.
Den primære analyse baseret på vurdering fra en uafhængig komité viste en statistisk signifikant reduktion på 45% i risikoen for sygdomsprogression eller død hos patienter med indolent nonHodgkin lymfom der fik Gazyvaro plus bendamustin efterfulgt af Gazyvaro vedligeholdelsesbehandling sammenlignet med patienter, der kun fik bendamustin. 
The primary analysis based on independent Review Committee (IRC) assessment demonstrated a statistically significant - 45% reduction in the risk of disease progression or death, in patients with iNHL receiving G+B followed by Gazyvaro maintenance, compared with patients receiving bendamustine alone.
• Du skal fortsætte med at bruge sikker prævention i 18 måneder, efter du har stoppet behandlingen med Gazyvaro. 
· Continue to use effective contraception for 18 months after stopping treatment with Gazyvaro.
Neutropeni§, trombocytopeni, anæmi, leukopeni 
Neutropenia§, thrombocytopenia, anaemia, leukopenia
Incidensen af hæmoragiske bivirkninger var ens på tværs af alle behandlingsarme. 
The incidence of haemorrhagic events was similar across all treatment arms.
Ialt 781 patienter randomiseredes i forholdet 2:2:1 til behandling med Gazyvaro plus chlorambucil, rituximab plus chlorambucil og chlorambucil alene. 
A total of 781 patients were randomised 2:2:1 to receive Gazyvaro plus chlorambucil, rituximab plus chlorambucil or chlorambucil alone.
Der er ikke indberettet infusionsrelaterede reaktioner af grad 3-5 efter den første infusion af 1000 mg i 1. behandlingsserie. 
No Grade 3-5 IRRs were reported beyond the first 1,000 mg infusions of Cycle 1.
Depression, angst 
Depression, anxiety
Hvis du har spørgsmål til hvordan denne medicin bruges, skal du kontakte lægen eller sundhedspersonalet. 
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Follikulært lymfom (FL) 
Follicular lymphoma (FL)
Der kan forekomme hypotension under intravenøs infusion af Gazyvaro. 
Hypotension may occur during Gazyvaro intravenous infusions.
Fire procent af patienterne behandlet med Gazyvaro plus chlorambucil oplevede akut trombocytopeni (forekom inden for 24 timer efter infusion af Gazyvaro) (se pkt. 
Four percent of patients treated with Gazyvaro plus chlorambucil experienced acute thrombocytopenia (occurring within 24 hours after the Gazyvaro infusion) (see section 4.4).
Ved behandling af tumorlysesyndrom korrigeres elektrolytafvigelser, nyrefunktionen og væskebalancen monitoreres og understøttende behandling initieres hvis indiceret, inklusive dialyse. 
For treatment of TLS, correct electrolyte abnormalities, monitor renal function and fluid balance, and administer supportive care, including dialysis as indicated.
Patienter der oplever neutropeni skal overvåges omhyggeligt med jævnlige blodprøver indtil neutropenien forsvinder. 
Patients who experience neutropenia should be closely monitored with regular laboratory tests until resolution.
Afsluttet mindst 1 time inden infusion af Gazyvaro 
Completed at least 1 hour prior to Gazyvaro infusion
* Kemoterapi: chlorambucil i kronisk lymfatisk leukæmi; bendamustin, CHOP, CVP i indolent non-Hodgikin lymfom herunder follikulært lymfom § Også observeret under vedligeholdelsesbehandlingen med mindst 2 % højere incidens i Gazyvaro-armen (BO21223) 
* Chemotherapy: Chlorambucil in CLL; bendamustine, CHOP, CVP in iNHL including FL § observed also during maintenance treatment with at least 2% higher incidence in Gazyvaro arm (BO21223)
Patienten bør henvises til neurolog for udredning og behandling af progressiv multifokal leukoencefalopati. 
The patient should be referred to a neurologist for the evaluation and treatment of PML.
Effektresultater for patienter med tidligere ubehandlet follikulært lymfom er opsummerede i tabel 8. 
Efficacy results for patients with previously untreated FL are summarised in Table 8.
INDHOLD ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 1000 mg/40 ml 
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 1,000 mg/40 mL
• Seks 28-dages behandlingsserier i kombination med bendamustin2 eller, 
· Six 28-day cycles in combination with bendamustine2 or,
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Gazyvaro i alle subgrupper af den pædiatriske population ved kronisk lymfatisk leukæmi og follikulært lymfom (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with Gazyvaro in all subsets of the paediatric population in CLLand FL (see section 4.2 for information on paediatric use).
Induktionsbehandling (i kombination med kemoterapi2) Gazyvaro bør administreres med kemoterapi som følger: 
Induction (in combination with chemotherapy2) Gazyvaro should be administered with chemotherapy as follows:
Samlet overlevelse (data er endnu ikke fuldstændige) Antal (%) patienter med hændelse Mediantid til hændelse (måneder) 
Overall Survival (not yet mature) No. (%) of patients with event Median time to event (months)
Patienter uden infusionsrelateret reaktion under den forudgående infusion 
Patients with no IRR during the previous infusion
• Kronisk lymfatisk leukæmi og follikulært lymfom er begge kræfttyper i blodet, der påvirker den type hvide blodlegemer, der hedder B lymfocytter. 
· CLL and FL are types of cancer that affect white blood cells called “B-lymphocytes”.
Obinutuzumabs farmakokinetik hos patienter med let (CrCl 5089 ml/min, n=464) eller middelsvær (CrCl 30 to 49 ml/min, n=106) nedsat nyrefunktion svarede til den hos patienter med normal nyrefunktion (CrCl ≥90 ml/min, n=383). 
Pharmacokinetics of obinutuzumab in patients with mild creatinine clearance (CrCl 50-89 mL/min, n=464) or moderate (CrCl 30 to 49 mL/min, n=106) renal impairment were similar to those in patients with normal renal function (CrCl ³ 90 mL/min, n=383).
Incidenserne præsenteret i de følgende afsnit, hvis der henvises til indolent non-Hodgkin lymfom er den højeste incidens af den specifikke bivirkning rapporteret fra et af de 2 pivotale studier (BO21223/GALLIUM, GAO4753g / GADOLIN). 
The incidences presented in the following sections if referring to iNHL are the highest incidence of that ADR reported from either pivotal study (BO21223/GALLIUM, GAO4753g/GADOLIN).
Gazyvaro + bendamustin efterfulgt af Gazyvaro vedligeholdelsesbehandling N=155 
Gazyvaro + Bendamustine followed by Gazyvaro maintenance N=155
Ved overdosering, bør infusionen straks afbrydes eller reduceres, og patienten overvåges nøje. 
Patients who experience overdose should have immediate interruption or reduction of their infusion and be closely supervised.
Serumkoncentrationer hos nyfødte på 28. dag postpartum lå inden for samme område som de maternelle serumkoncentrationer, hvorimod koncentrationer i mælken samme dag var meget lave (mindre end 0,5% af de tilsvarende maternelle serumkoncentrationer). 
Concentrations in infant serum on day 28 post-partum were in the range of concentrations in maternal serum, whereas concentrations in milk on the same day were very low (less than 0.5% of the corresponding maternal serum levels) suggesting that exposure of infants must have occurred in utero.
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejersken eller apoteket. 
If you get any side effects, talk to your doctor or nurse.
Forekomst og sværhedsgrad af infusionsrelaterede reaktioner faldt betydeligt efter de første 1000 mg var infunderet, og de fleste patienter oplevede ikke infusionsrelaterede reaktioner under efterfølgende infusioner af Gazyvaro (se pkt. 
The incidence and severity of infusion related symptoms decreased substantially after the first 1,000 mg was infused, with most patients having no IRRs during subsequent administrations of Gazyvaro (see section 4.8).
Evaluering af progressiv multifokal leukoencefalopati inkluderer, men er ikke begrænset til, vurdering af en neurolog, MR (magnetisk resonans)-skanning af hjernen og lumbalpunktur (cerebrospinalvæskeanalyse for John Cunningham virus-DNA). 
Evaluation of PML includes, but is not limited to, consultation with a neurologist, brain magnetic resonance imaging (MRI), and lumbar puncture (cerebrospinal fluid testing for John Cunningham viral DNA).
• Hvis du er gravid, har mistanke om at du er gravid eller planlægger at blive gravid, skal du kontakt lægen eller sundhedspersonalet. 
· Tell your doctor or nurse if you are pregnant, think you might be pregnant or are planning to have a baby.
Der blev ikke observeret post-baseline Human Anti-Human Antibody (HAHA) hos patienter med indolent non-Hodgkin lymfom behandlet i studie GAO4753g / GADOLIN. 
No post-baseline HAHA (Human Anti-Human Antibody) were observed in patients with iNHL treated in study GAO4753g/GADOLIN.
Der var ikke rapporteret trombocytopeni af grad 5. 
No Grade 5 events of thrombocytopenia were reported.
• Follikulært lymfom (også kaldet ”FL”) - Gazyvaro bruges til patienter, som ikke tidligere har været behandlet for follikulært lymfom - Gazyvaro bruges til patienter, som tidligere har fået mindst en behandling med et andet lægemiddel, kaldet rituximab, og hvor sygdommen er kommet igen eller blevet værre under eller efter behandlingen. 
· Follicular lymphoma (also called “FL”) Gazyvaro is used in patients who have not had any treatment for FL Gazyvaro is used in patients who have had at least one treatment with a medicine called rituximab before and whose FL has come back or got worse during or after this treatment.
Hos patienterne med follikulært lymfom forsinkede tillæg af Gazyvaro til bendamustin dog tiden til forværring af helbredsrelateret livskvalitet målt med FACT-Lym med en Trial Outcome Index score på 2,2 måneder (mediantid på 5,6 måned versus 7,8 måned for henholdsvis bendamustin og Gazyvaro plus bendamustin, hazard ratio = 0,83; 95% konfidensinterval 0,60; 1,13). 
However, in patients with FL the addition of Gazyvaro to bendamustine delayed the time to worsening of health-related quality of life as measured by the FACT-Lym TOI score by 2.2 months (median 5.6 versus 7.8 months for B and G+B respectively HR = 0.83; 95% CI: 0.60, 1.13).
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) Koncentrat til infusionsvæske, opløsning 1000 mg/40 ml 
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 1,000 mg/40 mL
Kaplan-Meyer kurver for progressionsfri overlevelse og samlet overlevelse er vist i figur 1-4. 
Kaplan-Meier curves for progression-free survival (PFS) and Overall Survival (OS) are shown in Figures 1-4.
Administration sammen med Gazyvaro havde ingen effekt på farmakokinetikken af bendamustin, FCkemoterapi, chlorambucil eller de enkelte komponenter i CHOP-kemoterapi. 
Co-administration with Gazyvaro had no effect on the pharmacokinetics of bendamustine, FC, chlorambucil or the individual components of CHOP.
Derudover medierer obinutuzumab in-vivo en mild grad af komplementafhængig cytotoksicitet. 
In addition, in vivo, obinutuzumab mediates a low degree of complement dependent cytotoxicity (CDC).
Patienterne blev randomiseret 1:1 til at få enten bendamustin alene (n=202) eller Gazyvaro i kombination med bendamustin (n=194) i seks behandlingsserier, hver af 28 dages varighed. 
Patients were randomised 1:1 to receive either bendamustine (B) alone (n = 202) or Gazyvaro in combination with bendamustine (G+B) (n = 194) for 6 cycles, each of 28 days duration.
Hvis du har haft nogen af disse symptomer inden behandlingen med Gazyvaro, skal du straks kontakte lægen, hvis de ændrer sig. 
If you had any of these symptoms before treatment with Gazyvaro, tell your doctor straight away if you notice any changes in them.
Forekomst af infusionsrelaterede reaktioner af grad 3-4 (baseret på et relativt lille antal patienter) var ensartet før og efter at tiltagene initieredes. 
The rates of Grade 3-4 IRRs (which were based on a relatively small number of patients) were similar before and after mitigation measures were implemented.
Incidensen af infektioner var 81 % i Gazyvaro plus kemoterapi-armen (grad 3-5 reaktioner blev rapporteret hos hhv. 22% af patienterne og dødelige reaktioner blev rapporteret hos 3% af patienterne. 
The incidence of infection was 81% in the Gazyvaro plus chemotherapy arm (with Grade 3-5 events reported in 22% of patients and fatal events reported in 3% of patients).
Symptomer, der anses for kortikale (fx afasi eller visuelrumlig desorientering) kan forekomme. 
Some signs/symptoms regarded as “cortical” (e.g. aphasia or visual-spatial disorientation) may occur.
Dosisjustering er ikke nødvendig til patienter med mild til moderat nedsat nyrefunktion (creatininclearance [CrCl] 30 - 89 ml/min) (se pkt. 
No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance [CrCl] 30-89 mL/min) (see section 5.2).
De hyppigst indrapporterede symptomer (≥ 5%) associeret med en infusionsrelateret reaktion var kvalme, opkastning, diarre, hovedpine, svimmelhed, træthed, kulderystelser, pyreksi, hypotension, ansigtsrødme, hypertension, takykardi,dyspnø og ubehag i brystet. 
Most frequently reported (≥ 5%) symptoms associated with an IRR were nausea, vomiting, diarrhoea, headache, dizziness, fatigue, chills, pyrexia, hypotension, flushing, hypertension, tachycardia, dyspnoea, and chest discomfort.
Rituximab + Kemoterapi efterfulgt af rituximab vedligeholdelsesbehandling N=601 
Rituximab + Chemotherapy followed by rituximab maintenance N=601
De hyppigste grad 3-5 bivirkninger var neutropeni (10%) samt anæmi, febril neutropeni, trombocytopeni, sepsis, øvre luftvejsinfektioner og urinvejsinfektioner (alle på 1%). 
The most common Grade 3-5 adverse reactions were neutropenia (10%), and anaemia, febrile neutropenia, thrombocytopenia, sepsis, upper respiratory tract infection, and urinary tract infection (all at 1%).
• Seks 28-dages behandlingsserier i kombination med bendamustin2 eller 
· Six 28-day cycles in combination with bendamustine2 or
Der er gennemført et fase III, internationalt klinisk multicenterstudie, ublindet, randomiseret, trearmet, 2 stadier (BO21004/CLL11) for at undersøge virkning og sikkerhed af Gazyvaro plus chlorambucil (GClb) sammenlignet med rituximab plus chlorambucil (RClb) eller chlorambucil alene (Clb). 
A Phase III international, multicentre, open label, randomised, two-stage, three-arm clinical study (BO21004/CLL11) investigating the efficacy and safety of Gazyvaro plus chlorambucil (GClb) compared to rituximab plus chlorambucil (RClb) or chlorambucil (Clb) alone was conducted in patients with previously untreated CLL with comorbidities.
Det skal gives som intravenøs infusion i separat infusionsslange efter fortynding. 
It should be given as an intravenous infusion through a dedicated line after dilution.
Den observerede forbedring i samlet overlevelse, set med Gazyvaro + bendamustin blev supporteret af en stratificeret hazard-ratio for den samlede overlevelse på 0,62 (95% konfidensinterval 0,39; 0,98) i denne post-hoc analyse. 
The observed improvement in OS seen with G+B was supported by a stratified HR for OS of 0.62 (95% CI: 0.39, 0.98) in this post hoc analysis.
Serumkoncentrationen af obinutuzumab hos afkommet svarede til de værdier, der sås hos deres mødre på 28. dagen efter fødslen, hvorimod koncentrationen i mælk på den samme dag var meget lave, hvilket tyder på, at obinutuzumab passerer blod-placenta-barrien (se pkt. 
Serum concentrations of obinutuzumab in offspring were similar to those in the mothers on day 28 post-partum, whereas concentrations in milk on the same day were very low, suggesting that obinutuzumab crosses the placenta (see section 5.3).
Profylakse og præmedicinering for infusionsrelaterede reaktioner 
Prophylaxis and premedication for infusion related reactions (IRRs)
35 måneders median observationstid 
Median observation time 35 months
Behandlingsdag 
Day of treatment
Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse Roche Pharma AG 
Name and address of the manufacturer responsible for batch release
For håndtering af symptomatiske bivirkninger (inklusiv infusionsrelaterede reaktioner), se afsnittet nedenfor (håndtering af infusionsrelaterede reaktioner eller pkt. 
For management of symptomatic adverse events (including IRRs), see paragraph below (Management of IRRs or section 4.4).
Håndtering af infusionsrelaterede reaktioner kan kræve midlertidig afbrydelse, nedsættelse af infusionshastighed eller seponering af Gazyvaro, som beskrevet nedenfor (se også pkt. 
Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of Gazyvaro as outlined below (see also section 4.4).
Antallet af dødelige hæmorrhagiske bivirkninger balancerede behandlingsgrupperne imellem, dog rapporteredes alle bivirkninger i Gazyvaro-armen i 1. behandlingsserie. 
The number of fatal haemorrhagic events was balanced between the treatment arms; however, all of the events in patients treated with Gazyvaro were reported in Cycle 1.
• Grad 4 (livstruende): Infusionen skal afbrydes og behandlingen permanent seponeres. 
· Grade 4 (life threatening): Infusion must be stopped and therapy must be permanently discontinued.
Gazyvaro er i kombination med bendamustin efterfulgt af Gazyvaro-vedligeholdelsesbehandling indiceret til behandling af patienter med follikulært lymfom, som ikke havde responderet på eller som progredierede under eller op til 6 måneder efter behandling med rituximab eller et behandlingsregime indeholdende rituximab. 
Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with FL who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
Efterfølgende behandlingsserier - 2-6 eller 2-8. 
Cycles 2-6 or 2-8
Der er ikke observeret nyretoksicitet med årsagssammenhæng med obinutuzumab hos mennesker. 
No renal toxicity with a causal relationship to obinutuzumab has been observed in humans.
42% af patienterne havde både en CrCl <70 ml/min og en co-morbiditetsscore over 6. 
Forty-two percent of patients enrolled had both a CrCl < 70 mL/min and a comorbidity score of > 6.
Antihistamin3 
Anti-histaminic medicine3
Kløe, nattesved 
Pruritus, night sweats
Der er udviklet en farmakokinetisk populationsmodel til at analysere farmakokinetiske data fra 469 patienter med indolent non-Hodgkin lymfom, 342 patienter med kronisk lymfatisk leukæmi og 130 patienter med diffust storcellet B-celle lymfom fra fase I-, fase II- og fase III-studier, som har været behandlet med obinutuzumab alene eller i kombination med kemoterapi. 
A population pharmacokinetic (PK) model was developed to analyse the PK data in 469 iNHL, 342 CLL and 130 diffuse large B-cell lymphoma (DLBCL) patients from Phase I, Phase II and Phase III studies who received obinutuzumab alone or in combination with chemotherapy.
• Hvis du har haft nogen af disse symptomer inden behandlingen med Gazyvaro, skal du straks kontakte lægen hvis symptomerne ændrer sig. 
· If you had any of these symptoms before treatment with Gazyvaro, tell your doctor straight away if you notice any changes in them.
Der er også rapporteret dødelige hæmoragiske bivirkninger under 1. behandlingsserie hos patienter behandlet med Gazyvaro. 
Fatal haemorrhagic events have also been reported in Cycle 1 in patients treated with Gazyvaro.
Infusionshastigheden kan øges forudsat patienten kan tolerere dette For håndtering af infusionsrelateret reaktion, der opstår under infusionen, se "Håndtering af infusionsrelaterede reaktioner". 
The infusion rate may be escalated provided that the patient can tolerate it. For management IRRs that occur during the infusion, refer to “Management of IRRs”.
• Kronisk lymfatisk leukæmi (også kaldet ”CLL”) - Gazyvaro bruges til patienter som ikke tidligere har været behandlet for kronisk lymfatisk leukæmi, og som har andre sygdomme, som gør, at de sandsynligvis ikke vil kunne tåle en fuld dosis af fludarabin, der er et andet lægemiddel som bruges til kronisk lymfatisk leukæmi. 
· Chronic lymphocytic leukaemia (also called “CLL”) Gazyvaro is used in patients who have not had any treatment for CLL before and who have other illnesses which make it unlikely that they would be able to tolerate a full dose of a different medicine used to treat CLL called fludarabine.
Det skal du vide, før du begynder at få Gazyvaro 
What you need to know before you are given Gazyvaro
Præmedicinering, der gives for at reducere risikoen for infusionsrelaterede reaktioner, er vist i tabel 1 (se også pkt. 
Premedication to reduce the risk of IRRs is outlined in Table 1 (see also section 4.4).
Efter intravenøs administration svarer fordelingsvolumen af det centrale kompartment (hhv. 2,98 l hos patienter med kronisk lymfatisk leukæmi og 2,97 l hos patienter med indolent non-Hodgkin lymfom) nogenlunde til serumvolumen. 
Following intravenous administration, the volume of distribution of the central compartment (2.98 L in patients with CLL and 2.97 in patients with iNHL), approximates serum volume, which indicates distribution is largely restricted to plasma and interstitial fluid.
Oral herpes, rinitis, faryngitis, lungeinfektion, influenza, nasofaryngitis 
Oral herpes, rhinitis, pharyngitis, lung infection, influenza nasopharyngitis
Den farmakokinetiske populationsanalyse af obinutuzumab viste, at creatininclearance ikke påvirker obinutuzumabs farmakokinetik. 
The population pharmacokinetic analysis of obinutuzumab showed that creatinine clearance does not affect pharmacokinetics of obinutuzumab.
34 måneders median observationstid 
Median observation time 34 months
De hyppigst indberettede andre samtidige sygdomme (med en cut-off på 30% eller derover) i MedDRA-systemet var: Vaskulære sygdomme (73%), hjertesygdomme (46%), sygdomme i mavetarm-kanalen (38%), stofskifte- og ernæringssygdomme (40%), sygdomme i nyrer og urinveje (38%), sygdomme i knogler, led, muskler og bindevæv (33%). 
The most frequently reported coexisting medical conditions (using a cut off of 30% or higher), in the MedDRA body systems are: Vascular disorders (73%), Cardiac disorders (46%), Gastrointestinal disorders (38%), Metabolism and nutrition disorders (40%), Renal and urinary disorders (38%), Musculoskeletal and connective tissue disorders (33%).
Intravenøst kortikosteroid1,4(obligatorisk for kronisk lymfatisk leukæmi og anbefalet for follikulært lymfom) 
Intravenous corticosteroid1,4 (mandatory for CLL, recommended for FL)
Kronisk lymfatisk leukæmi (i kombination med chlorambucil1) 
Chronic lymphocytic leukaemia (in combination with chlorambucil1)